Caribou Biosciences, Inc. (CRBU) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Caribou Biosciences is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using its CRISPR chRDNA platform. The company is currently advancing two primary clinical candidates: CB-010 (anti-CD19) and CB-011 (anti-BCMA). During the quarter, the company executed a strategic pipeline prioritization, discontinuing the CB-010 lupus program (GALLOP trial) and the CB-012 AML program (AMpLify trial), resulting in a workforce reduction of approximately 32%.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value (in thousands) |
|---|---|
| Revenue (Licensing & Collaboration) | $5,020 |
| Net Loss | $(94,089) |
| Net Loss Per Share (Basic & Diluted) | $(1.01) |
| Operating Cash Flow (Used) | $(64,983) |
| Cash, Cash Equivalents & Marketable Securities | $183,948 |
| Total Assets | $220,903 |
| Accumulated Deficit | $(542,479) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $0.9 million (15%) compared to the six months ended June 30, 2024, primarily due to the cessation of revenue recognition from the Edge Animal Health license agreement ($1.6 million decrease), partially offset by increases from other licensees.
- Significant Impairment Charges: The company recorded $12.2 million in impairment charges related to the strategic restructuring. This includes $7.4 million for tenant improvements, $2.6 million for right-of-use assets, and $2.2 million for unused laboratory equipment.
- Equity Investment Impairment: A non-cash impairment charge of $9.2 million was recorded for the company's equity investment in Edge Animal Health, reducing the carrying value to zero.
- Expense Reduction: Research and Development (R&D) expenses decreased by $6.0 million and General and Administrative (G&A) expenses decreased by $6.0 million year-over-year, driven by workforce reductions and the discontinuation of specific clinical programs.
- MSKCC Liability: The company terminated its agreement with Memorial Sloan Kettering Cancer Center (MSKCC), resulting in the fair value of the success payments liability being reduced to zero, generating a gain of $0.8 million.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities of approximately $184 million to be sufficient to fund operations for at least the next 12 months from the filing date.
- Capital Requirements: The company anticipates needing to raise additional capital in the future to support clinical development and commercialization efforts. It has a refreshed At-The-Market (ATM) equity offering program with up to $100 million available under a new 2025 Shelf Registration Statement.
- Nasdaq Listing Compliance: The company received a notice in May 2025 regarding non-compliance with the Nasdaq Minimum Bid Price Rule (stock price below $1.00). The company regained compliance in June 2025. Stockholders have approved a reverse stock split (ratio 1-for-5 to 1-for-50) to be implemented at the Board's discretion to maintain listing standards.
- Legal Proceedings: A putative class action lawsuit (Saylor Case) was voluntarily dismissed without prejudice in April 2025. However, a consolidated shareholder derivative action remains pending, challenging disclosures regarding clinical results and financial statements.
- Regulatory/Tax: The company is evaluating the impact of the "One Big Beautiful Bill Act" enacted in July 2025 on its deferred taxes and regulatory provisions.
Investor Verification Checklist
- Runway Validation: Verify the $184 million liquidity position against current burn rates to confirm the 12-month runway estimate.
- Restructuring Completion: Confirm that the $14.2 million in total restructuring and impairment costs (severance, wind-down, and asset impairments) are fully recognized and that no further material charges are expected.
- Edge Investment Status: Review the rationale for the full impairment of the Edge Animal Health investment and assess any remaining contractual obligations or rights.
- Stock Price Stability: Monitor the stock price relative to the $1.00 Nasdaq threshold and the potential timing/impact of a reverse stock split.
- Clinical Progress: Track enrollment and data readouts for the remaining core programs, CB-010 (ANTLER trial) and CB-011 (CaMMouflage trial), as these are now the sole focus of R&D spending.